

To whom it may concern:

Company Name: TOHO HOLDINGS CO., LTD.
Corporate Representative: Atsushi Udoh, Representative Director, CEO
(Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact: Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division
(TEL: 81-3-6838-2803)

Conclusion of Capital and Business Alliance with MICIN, Inc.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh; hereinafter “TOHO HOLDINGS”) announces that it has agreed to enter into a capital and business alliance with MICIN, Inc. (Headquarters: Tokyo; Representative CEO: Seigo Hara; hereinafter “MICIN”), as described below.

1. Reason for the business alliance

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Toward the realization of its vision, “FOR ALL TO LIVE OUT THEIR LIVES WITH DIGNITY”, MICIN is engaged in Telehealth business (Telemedicine service “curon”, etc.), Decentralized clinical trials business (DCT (*1) support system “MiROHA”, etc.), Digital therapeutics (*2) business, Insurance business, etc. aimed at providing diagnosis, treatment, and security tailored to the individual’s needs.

In its Medium-term Management Plan 2023-2025 “Create the Next Generation”, TOHO HOLDINGS has set “Investment for growth and improvement of profitability” as one of its basic policies and is determined to push ahead with concrete measures such as “Evolution of customer support business” by actively promoting alliances and DX. The capital and business alliance is expected to generate synergies between TOHO HOLDINGS’ pharmaceutical wholesaling, dispensing pharmacy, customer support system, and other businesses and MICIN’s businesses, and will contribute to solving various issues in the healthcare field and enhance corporate value over the medium to long term.

*1 Decentralized Clinical Trial. To conduct a clinical trial by combining data collection at the patient’s home or at a partner medical institution, etc., without necessarily depending on a visit to the study site.

*2 Software-assisted therapeutic interventions based on medical evidence that support not only disease management, but also disease prevention and treatment.

2. Overview of MICIN

- (1) Company name: MICIN, Inc.
- (2) Location: 12F, TOKIWA BRIDGE, 2-7-1, Otemachi, Chiyoda-ku, Tokyo, 100-0004
- (3) Representative: Seigo Hara, Representative CEO
- (4) Established: November 26, 2015
- (5) Business content: Telehealth Business, Decentralized Clinical Trials Business, Digital therapeutics Business, Insurance Business, etc.
- (6) Capital: 100 million yen

3. Forward looking outlook

The impact of this business alliance on the Company’s business performance is expected to be minimal, but the Company will disclose any impact promptly if it becomes necessary to do so in the future.